IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No.	:	PCT/JP2003/011590
International Filing Date	:	10 September 2003 (10.09.2003)
Priority Date(s) Claimed	:	10 September 2002 (10.09.2002)
Applicant(s) (DO/EO/US)	:	Yuji OHASHI et al.

Title: WHITENING AGENT CONTAINING CRYSTALLINE MOLECULAR COMPLEX OF HYDROQUINONE AND SURFACTANT

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

\boxtimes		37 C.F.R. § 1.97(b), no fee or statement is required for filing this information sure statement is filed:
		within three months of the filing date of a national application other than a CPA under § 1.53(d);
	\boxtimes	within three months of the actual filing date of the national phase of a PCT application; OR
		before the mailing of a first substantive office action (including after filing of an RCE).
		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods ed in 37 C.F.R. § 1.97(b), but before the mailing date of:
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and

	is acco	mpanied by:
		the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
		a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
		R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
	a final	action under 37 C.F.R. § 1.113;
	termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
	OR a n	notice of allowance under 37 C.F.R. § 1.311;
AND i	s filed o	on or before payment of the issue fee; AND is accompanied by:
		tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 0 under 37 C.F.R. § 1.17(p).
ents Un	der 37	C.F.R. 1.97(e)
		Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
		No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
<u> </u>	<u>s</u>	
	ancesto	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
\boxtimes	_	of materials listed but not attached were cited in an international search dated 24 December 2003.
	Not re	quired by 37 CFR § 1.98.
	Copies	s of the materials listed are attached (except for the foregoing).
	date of	Under 37 C.F.: date of the foll a final termin OR a r AND is filed of the stat \$180.0 cnts Under 37

Non-English Language References 冈 An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s). A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below: X =document of particular relevance when it is taken alone document of particular relevance when it is combined with another such Y =document A =document defining the general state of the art non-written disclosure O =P =intercalated document document cited to understand the theory or principle underlying the T =invention E =patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date D =cited in the application cited for another reason L =& = publication of member of same patent family Translation of other relevant information on foreign search report Other Information Payment of Fees Due (If Any):

A check for \$ covering the fee identified above is attached.					
Please charge to Deposit Account No. 13-3402 \$	for the fee identified above.				

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza l
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: AOKI-0011

Date: March 9, 2005

AJZ:ssr



Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

mation unless it contains a valid OMB control number. 078

Substitute	e for form 1449A/PT()			Complete if Known AU/ 2 CM		
				Application Number	USNP of PCT/JP2003/011590		
INFO	RMATION	DIS	CLOSURE	Filing Date	10 September 2003 (10.09.2003)		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Yuji OHASHI et al.		
				Group Art Unit	unknown		
	(use as many she	eets as	necessary)	Examiner Name	unknown		
Sheet	1	of	2	Attorney Docket Number	AOKI-0011		

	U.S. PATENT DOCUMENTS							
		U.S. Patent Document			Date of Publication of Cited Document			
Examiner Initials *	Cite No.1		(ind Code ² (if known)	Name of Patentee or Applicant of Cited Document	MM-DD-YYYY			

		Foreign Patent Document		Foreign Patent Document		Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T⁵
	001	JP	2001-302576		ZAIDAN HOJIN RIKOGAKU SHINKOKAI	10-31-2001		
	002	WO	01/91715		PENTAPHARM LTD.	12-06-2001		
	003	JP	9-77654		SHISEIDO CO., LTD.	03-25-1997		
	004	JP	63-246311		SHISEIDO CO., LTD.	10-13-1988		

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents, ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.



Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number Complete if Known ー サイカの Substitute for form 1449A/PTO Application Number USNP of PCT/JP2003/011590 INFORMATION DISCLOSURE Filing Date 10 September 2003 (10.09.2003) STATEMENT BY APPLICANT Yuji OHASHI et al. First Named Inventor Group Art Unit unknown (use as many sheets as necessary) **Examiner Name** unknown Sheet 2 of Attorney Docket Number **AOKI-0011**

Examiner		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), votume-issue number(s), publisher, city and/or country where published.	
Initials *	Cite No.1		T 2
	005	N. IIMURA ET AL.: "COMPLEX FORMATION BETWEEN CATIONIC SURFACTANTS AND INSOLUBLE DRUGS", BULL. CHEM. SCO. JPN., 1999 vol. 72, pages 2417-2422	
		·	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.